1/23/09 update
The inauguration of President Obama (wow, it's really true!) did not, regrettably, inaugurate a bull market on Wall Street. That should be no big surprise. After all, as the new Commander in Chief implied in his inaugural address, our nation does include a fair share of "non-believers."
For the week, the Nasdaq Composite Index was down -6.00% CYTD, or "Contest Year To Date" (vs. down -2.69% CYTD a week ago). The Nasdaq Biotech Index also declined for the week, closing down -1.32% CYTD (vs. up 2.24% CYTD a week ago). And the Contest median closed down -3.08% CYTD (vs. up .91% CYTD a week ago).
(Since the Friday, 1/9/09 closing quotes were used as the 2009 Contest starting prices, I decided to use CYTD, for "Contest Year To Date," rather than YTD in my updates.)
ENZYME's portfolio took over first place, closing the week up 6.29% CYTD, the gain being mostly due to the jump by the portfolio's penny stock stem cell play, ACTC. Stem Cell stocks were boosted by news that the FDA gave the go ahead for Geron's embryonic stem cell clinical trial. My own portfolio, also helped a bit by a stem cell play, ASTM, managed to land in second place with a 5.25% CYTD gain.
At Friday's close, 11 of the 32 Contest portfolios were in the black and 15 of the 32 beat the NBI.
Enjoy the 1st Obama weekend folks!
Below is the Top Ten list on 1/23/09:
1/23/09
Rank Name Profit/Loss
1 ENZYME 6,294
2 BULBA 5,254
3 ROBERT 4,797
4 RKRW 4,329
5 FILO 3,364
6 GHMM 3,119
7 THEOX 1,812
8 ASHLEY 1,021
9 SCARAM 231
10 JACKH 142
(All corrections, especially adjustments for splits, greatly appreciated.) |
